|Bid||0.00 x 800|
|Ask||23.07 x 900|
|Day's Range||22.33 - 23.63|
|52 Week Range||19.45 - 67.84|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||48.43|
Subscribe to Yahoo Finance Plus to view Fair Value for VALN
Saint Herblain (France), May 25, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the successful completion of the lot-to-lot Phase 3 trial of its single-shot chikungunya vaccine candidate, VLA1553. The final analysis included six-month follow-up data and confirmed the topline results reported in December 2021. The VLA1553-302 trial met its primary endpoint, demonstrating that three consecutively manufactured vaccine lots elicited equivalent imm
Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.
What happened Several days after experiencing a pleasant share price pop on good regulatory news, Dynavax (NASDAQ: DVAX) repeated the feat on Thursday. An important partner for the company reported an encouraging development that morning, also in the regulatory sphere.